Subjects: PDT, TRI
Novartis Launches Joint Working Project with the Royal Marsden Partners Cancer Vanguard to Improve Quality of Care and Increase Satisfaction Among Cancer Patients
FRIMLEY, England, November 8, 2017 /PRNewswire/ --
- First pilot of a new cancer care model which leverages the role of the pharmacist by the Vanguard New Models of Care Programme
- Programme will improve cancer patient care across a catchment population of 3.5 million people
- New care model may be adopted at other NHS sites following completion of the Joint Working Project
Novartis today announced the launch of The Royal Marsden Partners Cancer Vanguard (RMP) Oncology Pharmacy Service Improvement Joint Working Project. Cancer patients living in North West and South West London will now benefit from the Joint Working Project which will aim to improve the quality of cancer patient care. The project, run by Novartis and the Royal Marsden, will run for up to two years as a pilot with the potential to be expanded across other NHS sites.
One in two people will now develop cancer in their lifetime and with recent research showing cancer care targets are being missed across the UK, improving the breadth and quality of care patients receive is essential[1],[2]. The Royal Marsden Partners Cancer Vanguard (RMP) Oncology Pharmacy Service Improvement Joint Working Project will help to address the increasing demand on the oncology service. Assessing the current oncology pharmacy service functions and skill mix supporting clinical teams, the project will then introduce new models of care to improve the delivery of treatment and enhance the quality and consistency of care for patients.
Novartis and the NHS team will combine their expertise, resources, and time to improve patient care in the main solid tumour pathways, including advanced melanoma, breast, lung, and renal cell carcinoma. This partnership is expected to provide quantifiable improvements for patients including ensuring quick access to appropriate treatments, accurate drug prescription verification, and address issues with the delivery of treatments, for instance using a mobile chemotherapy bus service to increase convenience to patients.
"Expanding and enhancing the role of oncology pharmacists will help us to address the increasing pressures on cancer services," said Jatinder Harchowal, Chief Pharmacist and Clinical Director, Medicines Management & Clinical Support Services, Royal Marsden NHS Foundation Trust. "We are optimistic that the models being trialled here could lead to a significant impact at a national level for cancer patients."
Central to this Joint Working Project will be the introduction of two new roles, a Consultant Oncology Pharmacist and a New Care Models Pharmacist, who will work in unison to oversee implementation of new models of care. This marks the first project initiated as part of the Vanguard New Models of Care Programme that leverages the role of the pharmacist.
As well as providing benefits to patients, the project will also benefit the RMP by establishing best practice protocols in oncology pharmacy service functions that can be implemented across all nine RMP hospitals. The project will also establish a new weekly Consultant Oncology Pharmacist clinic at the Royal Marsden hospital, to provide enhanced care for patients.
Barak Palatchi, Oncology General Manager, Novartis UK & Ireland, said, "We are proud of our collaborations with the NHS, and believe that Joint Working Projects such as this are vital for advancing oncology care and services, ultimately leading to improving cancer patient outcomes. This project underpins Novartis' commitment to patient care, from diagnosis through to treatment, and we look forward to pooling our expertise and resources with the RMP and improving the patient experience."
The expected improvements in oncology pharmacy functions will be measured against service standards in the NICE treatment guidelines and the Revised Chemotherapy Measures for the Manual for Cancer Services 2011[3].
This project marks one of 28 Joint Working Projects that Novartis has undertaken with the NHS to date, working in partnership towards the common goal of improving outcomes for patients.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 121,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
In the UK, Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. Based on four sites across the north and south of England, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis by manufacturing the active pharmaceutical ingredients used worldwide in many medicines. In 2016 Novartis in the UK invested almost £40million in R&D and is the largest commercial sponsor of clinical trials. For more information, please visit http://www.novartis.co.uk.
Novartis UK is on Twitter. Sign up to follow @NovartisUK at https://twitter.com/novartisuk
For Novartis multimedia content, please visit https://www.novartis.co.uk/news/media-library
References
- Ahmad A.S., Ormiston-Smith N. & Sasieni P.D. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. British Journal of Cancer, 2015:112; 942-947.
- NHS waits for cancer care, A&E and ops worsen across UK. http://www.bbc.co.uk/news/health-41656667. Last Accessed: October 2017.
- Revised Chemotherapy Measures for the Manual for Cancer Services 2011. https://www.gov.uk/government/publications/revised-chemotherapy-measures-for-the-manual-for-cancer-services. Last Accessed: October 2017.
Novartis UK Media Contacts
Novartis UK Press Office
Tel: +44-1276-698-691
E-mail: [email protected]
These press releases may also interest you
|
News published on and distributed by:
